gemcitabine has been researched along with cp 31398 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blandino, G; Cordani, M; Di Agostino, S; Donadelli, M; Fiorini, C; Padroni, C | 1 |
| Chen, Y; Tian, B; Wang, L; Wang, W; Zhang, Y; Zhu, Y | 1 |
2 other study(ies) available for gemcitabine and cp 31398
| Article | Year |
|---|---|
Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Mutation; Pancreatic Neoplasms; Phosphorylation; Pyrimidines; Tumor Suppressor Protein p53 | 2015 |
Gemcitabine treatment induces endoplasmic reticular (ER) stress and subsequently upregulates urokinase plasminogen activator (uPA) to block mitochondrial-dependent apoptosis in Panc-1 cancer stem-like cells (CSCs).
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Deoxycytidine; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Gemcitabine; Heat-Shock Proteins; Humans; Mitochondria; Neoplastic Stem Cells; Pancreas; Pancreatic Neoplasms; Pyrimidines; Tumor Suppressor Protein p53; Urokinase-Type Plasminogen Activator | 2017 |